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The hexameric AAAATPase p97 is involved in several
human proteinopathies and mediates ubiquitin-
dependent protein degradation among other essen-
tial cellular processes. Via its N-terminal domain (N
domain), p97 interacts with multiple regulatory co-
factors including the UFD1/NPL4 heterodimer and
members of the ‘‘ubiquitin regulatory X’’ (UBX)
domain protein family; however, the principles gov-
erning cofactor selectivity remain to be deciphered.
Our crystal structure of the FAS-associated factor 1
(FAF1)UBX domain in complex with the p97N domain
reveals that the signature Phe-Pro-Arg motif known
to be crucial for interactions of UBX domains with
p97 adopts a cis-proline configuration, in contrast
to a cis-trans mixture we derive for the isolated
FAF1UBX domain. Biochemical studies confirm that
binding critically depends on a proline at this posi-
tion. Furthermore, we observe that the UBX proteins
FAF1 and UBXD7 only bind to p97-UFD1/NPL4, but
not free p97, thus demonstrating for the first time
a hierarchy in p97-cofactor interactions.
INTRODUCTION
The hexameric AAA ATPase (ATPase associated with various
activities) p97, also referred to as valosin-containing protein
(VCP), participates in a large variety of cellular processes
including protein quality and cell cycle control, membrane
fusion, transcriptional activation, DNA-damage repair, apo-
ptosis, and autophagy (Halawani and Latterich, 2006; Schuberth
and Buchberger, 2008; Vij, 2008; Ye, 2006). p97 plays a central
role in the ubiquitin proteasome system (UPS), for instance in
the endoplasmic reticulum-associated degradation (ERAD)
pathway, where it catalyzes the ATP-driven extraction of mis-
folded proteins from the ER back into the cytoplasm, and serves
as a molecular chaperone, guiding ubiquitylated substrates to
the 26S proteasome for degradation (Hirsch et al., 2009).
p97 mediates these diverse cellular processes with the help of
various adaptor proteins that specifically recruit ubiquitylated
substrates (Yeung et al., 2008). This enzyme is composed (DeLa-
Barre and Brunger, 2003; Zhang et al., 2000) of two ATPase
domains (D1 and D2) and an N-terminal domain (N domain) toStructure 19which most adaptor proteins bind. The two best-characterized
adaptors of p97 are p47 and the UFD1/NPL4 heterodimer, which
bind to the N domain in a mutually exclusive manner (Bruderer
et al., 2004; Meyer et al., 2000) and target p97 to membrane
fusion events and the ERAD pathway, respectively. Both com-
plexes differ significantly in stoichiometry and symmetry, reflect-
ing their specific actions and ability to interact with additional
adaptors that cooperate with p97 in diverse cellular pathways
(Dreveny et al., 2004; Pye et al., 2007).
Proteins that contain the so-called ubiquitin regulatory X (UBX)
domain, which features a ubiquitin-like fold, constitute the
largest family of p97 adaptor proteins and bind to the N domain
through a highly conserved R.FPR motif of exposed side
chains (Buchberger et al., 2001; Dreveny et al., 2004; Schuberth
andBuchberger, 2008). In humans, 13members have been iden-
tified that can be divided into two major subclasses based on
their ability to bind ubiquitylated substrates (Alexandru et al.,
2008; Schuberth and Buchberger, 2008): (i) UBX-only proteins
(p37, ASPL, UBXD1 to UBXD6); and (ii) UBA-UBX proteins
(p47, FAF1, SAKS1, UBXD7, UBXD8). The second group con-
tains an N-terminal ubiquitin-associated (UBA) domain involved
in substrate binding, and a C-terminal UBX domain mediating
interactions with p97. These proteins also associate with a large
number of ubiquitin ligases. However, not all UBX proteins
interact with p97 through their UBX domain. For example the
UBX-only protein UBXD1 that lacks the conserved FPR signa-
ture instead utilizes a so-called bipartite-binding mechanism in
which two separate regions of UBXD1 interact with p97, in this
case with its N domain and its C terminus (Kern et al., 2009).
In the ERAD pathway UBX proteins are involved in the
retro-translocation of misfolded proteins into the cytoplasm by
recruiting p97 to the ER membrane as well as in the targeting
of polyubiquitylated substrates to p97 and the proteasome.
FAF1 (FAS-associated factor 1), a UBA-UBX protein composed
of multiple protein-interacting domains, has been implicated as
a tumor suppressor that is involved in the regulation of apoptosis
and NF-kB activity, as well as in ubiquitylation and proteasomal
degradation (Menges et al., 2009). UBXD7, another UBA-UBX
protein, has been shown to link p97 to the ubiquitin ligase
CUL2/VHL and its substrate hypoxia-inducible factor 1a
(HIF1a) (Alexandru et al., 2008).
p97 itself has been implicated in cancer and a wide variety of
neurodegenerative disorders, including Parkinson’s disease,
Lewy body disease, Huntington’s disease, and spinocerebellar
ataxia type III (SCAIII; Machado-Joseph disease) (Haines,
2010). Mutations in p97 cause inclusion bodymyopathy, Paget’s
disease of the bone, and frontotemporal dementia (IBMPFD),, 833–843, June 8, 2011 ª2011 Elsevier Ltd All rights reserved 833
Table 1. Data Collection and Refinement Statistics
p97N FAF1UBX
p97N-
FAF1UBX
Data Collection
Wavelength (A˚) 0.9184 0.9792 0.9184
Space group P31 P61 P65
Cell dimensions
a = b, c (A˚) 60.1, 63.1 92.6, 108.5 88.1, 66.9
a = b, g () 90,120 90,120 90, 120
Resolution (A˚)a 40.34–2.65
(2.79–2.65)
80.34–3.0
(3.16–3.0)
38.14–2.0
(2.11–2.0)
<I/s(I)>a,b 16.4 (2.7) 12.5 (2.9) 16.5 (3.9)
Completeness (%)a 100 (100) 100 (100) 98.5 (97.8)
Redundancya 4.5 (4.5) 5.2 (3.6) 7.7 (7.7)
Rsym
a,c 5.0 (57.3) 9.5 (51.8) 7.7 (53.4)
Refinement
Resolution (A˚) 30.28–2.65 42.65–3.0 33.14–2.0
Number of reflections 7,267 10,401 19,395
Rcryst/Rfree
d 19.5/23.6 17.8/25.8 16.9/21.0
Number of atoms
Protein 1,346 2,767 2,114
Ligands 16 15 1
Water 16 24 146
Rmsd
Bond lengths (A˚) 0.012 0.009 0.007
Bond angles () 1.351 1.324 1.103
Estimated coordinate error (A˚)e 0.43 0.43 0.21
B factors (A˚2)
Protein (p97N/UBX) 76.8/– –/54.1 34.7/44.7
Water 65.4 43.9 41.1
Ramachandran statisticsf
Favored (%) 94.0 93.2 96.6
Allowed (%) 3.0 4.9 3.4
Outliers (%) 3.0 1.9 0
aNumbers in parentheses refer to the respective highest resolution data
shell in each data set.
b <I/sI> indicates the average of the intensity divided by its average
standard deviation.
c Rsym = ShklSijIi < I > j/ShklSi < I >, where Ii is the ith measurement,
and < I > is the weighted mean of all measurements of I.
d Rcryst = SkFoj  jFck/SjFoj, where Fo and Fc are the observed and calcu-
lated structure factor amplitudes. Rfree is the same as Rcryst for 5% of the
data randomly omitted from the refinement.
e Estimated coordinate error based on Rfree.
f Ramachandran statistics indicate the fraction of residues in the favored
(98%), allowed (>99.8%), and disallowed regions of the Ramachandran
diagram, as defined by MolProbity (Davis et al., 2007).
Structure
Sequential Cofactor Binding to p97a rare proteinopathy that mainly affects skeletal muscle, brain,
and bone (Ju andWeihl, 2010).Mutations in p97 also cause auto-
somal-dominantly inherited amyotrophic lateral sclerosis (ALS),
a fatal neurodegenerative disease characterized by motor neu-
ron degeneration (Johnson et al., 2010).
In order to understand themechanism underlying p97 cofactor
selectivity and its role in ubiquitin-dependent protein degrada-834 Structure 19, 833–843, June 8, 2011 ª2011 Elsevier Ltd All rightstion, we have characterized the interaction between UBA-UBX
containing cofactors and p97. The crystal structure of p97N in
complex with FAF1UBX as well as a detailed biochemical anal-
ysis of the p97-binding site revealed a conserved binding
mode of the UBX R.FPR signature to the hydrophobic cleft
formed between the two p97N subdomains. Biochemical studies
demonstrate that FAF1 and UBXD7 only bind to p97-UFD1/
NPL4, but not to free p97, thus demonstrating for the first time
a hierarchy in p97-cofactor interactions.
RESULTS
FAF1UBX Binds into the p97N Domain Hydrophobic
Interdomain Cleft
To obtain molecular details of the p97-FAF1 interaction, we
solved the crystal structures of the p97N domain in complex
with the FAF1UBX domain and in the free state. The apo form
of the N domain was solved by molecular replacement with the
N domain of the p97ND1 crystal structure as search model
(PDB entry 1S3S) and was refined at 2.65 A˚ resolution to a
crystallographic R factor of 19.5% and a free R factor of
23.6% (Table 1). The p97N-FAF1UBX complex was also solved
by molecular replacement with the same search model for the N
domain and the NMR structure of the FAF1UBX domain (Model 1
of PDB entry 1H8C) and was refined at 2.0 A˚ resolution to a
crystallographic R factor of 16.9% and a free R factor of
21.0% (Table 1). As described earlier (DeLaBarre and Brunger,
2003; Zhang et al., 2000), the p97N domain (residues 10–186)
contains two subdomains linked by a flexible linker of six amino
acids: an N-terminal double c b-barrel (referred to as either Nn or
Na); and a C-terminal a+b domain (Nc or Nb) with a central four-
stranded antiparallel b sheet (Figure 1A). The FAF1UBX domain
encompasses residues 570–649 and adopts the b-grasp
(b-b-a-b-b-a-b) or ubiquitin-like fold, which is characterized by
a five-stranded antiparallel b sheet (Figure 1A), a single helix on
top of the b sheet, and a short 310 helix inserted between
b strands 4 and 5 (Buchberger et al., 2001).
The p97N-FAF1UBX interface is predominantly polar with 29%
charged and 46% polar residues and only 25% nonpolar resi-
dues. The most critical interaction is located in the UBX loop
region between b strands 3 and 4, the S3/S4 loop with the
sequence 618TFPR621, that is an essential part of the conserved
UBX 579R.619FPR621 signature motif. The aromatic side chain
of Phe619 of the UBX domain inserts into a hydrophobic cleft
created between the two N-terminal subdomains of p97 (Fig-
ure 1B). Val38, Phe52, Ile70, Leu72, Tyr110, and Tyr143 create
this binding pocket and are involved in several hydrophobic
interactions with UBX Leu616, Phe619, and Phe645 (Figure 1C).
This pocket is restricted at its base by a salt bridge formed
between Arg144 and Asp35 (NH2-OD2 3.2 A˚ and NH1-OD1
2.9 A˚) that connects the Nn and Nc subdomains. In addition to
these hydrophobic contacts, several main chain-side chain and
side chain-side chain hydrogen bonds are observed, including
Arg621 of FAF1 and Arg53 of p97 (Figure 1C). Arg53 also forms
a hydrogen bond with the carbonyl oxygen of Phe619, which
apparently stabilizes the S3/S4 loop conformation. UBX Arg579,
thefirst arginineof theconservedUBX579R.619FPR621 signature
motif, is deeply buried in p97N and is 3.8 A˚ from the carbonyl
oxygen of Val108, which is classified as a hydrogen bond despitereserved
Figure 1. Structure of p97N in Complex with the UBX Domain of FAF1
(A) Ribbon and surface representation of the overall structure. The UBX domain is shown in gold and p97N in gray.
(B) Surface representation of the binding pocket on the N domain. The UBX domain and p97N are colored as in (A). Hydrophobic residues of p97 are colored in
green, acidic residues in red, and basic residues in blue.
(C) Stereo view of the interface. Residues involved in binding are shown in stick representation. Carbon atoms of p97 residues are colored in gray and for
FAF1UBX in gold. Dashed lines indicate H bonds.
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Sequential Cofactor Binding to p97the long distance by the program PDBePISA (Figure 1C). In
addition to its S3/S4 loop, UBX binds via its N-terminal b strand
S1 (Lys575, Arg579) and its C-terminal b strand S5 (Gln641,
Glu642, Thr643, Phe645, Glu647) to p97 (Figure 1C). Residues
from connecting loops of both subdomains of p97 contribute to
the p97-FAF1 interface. These residues contact the surface of
the UBX b sheet in the region around b strands 1, 3, 4, and 5.
This binding mode of p97 in which it interacts with the hydro-
phobic surface of the UBX b sheet resembles the recognition
of ubiquitin by a large number of so-called ubiquitin-binding
domains (UBDs) (Dikic et al., 2009). UBDs are structurally diverse
motifs that recognize and bind to ubiquitin as well as proteins
sharing the ubiquitin-like fold such as the UBX domain. Most
UBDs use a-helical structures to bind to the hydrophobic patch
in the b sheet of ubiquitin centered on Ile44. Ile44 corresponds to
Leu616 in FAF1UBX, and this residue is located in b strand S3
that precedes the S3/S4 loop. In contrast to the a-helical
UBDs, the p97 interaction site is located in the cleft between
the two N-terminal subdomains, and p97 recognizes the corre-
sponding hydrophobic patch via loop elements. Therefore, this
interaction is distinct from that observed for canonical UBDs.
The Conserved R.FPR Signature of FAF1UBX Features
a cis-Proline
The structures of the N domain of p97 in its apo state and in
complex with the FAF1UBX domain can be superimposed with
a root-mean-square deviation (rmsd) of 0.7 A˚. Nevertheless,Structure 19subtle conformational changes induced by UBX binding are
obvious. Phe52, Arg53, and Glu141 show significant differences
in the orientations of their side chains (see Figure S1 available
online). All three side chains in the apo structure are flipped
away from the putative interaction interface, whereas they are
involved in either hydrogen bonding or hydrophobic interactions
in the p97N-FAF1UBX structure.
A closer examination of the p97N-FAF1UBX complex struc-
ture revealed that two proline residues, Pro620 in the conserved
and essential S3/S4 loop as well as the nonconserved Pro640 in
the 310/S5 loop, adopt the cis-isomer in the complex structure.
To investigate whether theses proline residues are already in
the cis-configuration prior to p97 binding, or whether this interac-
tion induced a trans- to cis-isomerization, we also determined
the apo structure of FAF1UBX. This structure was solved by
molecular replacement with the FAF1UBX domain of the p97N-
FAF1UBX complex crystal structure as search model, and was
refined at 3.0 A˚ resolution to a crystallographic R factor of
17.8% and a free R factor of 25.8% (Table 1). Four FAF1UBX
monomers (referred to as A–D) are present in the asymmetric
unit. The four FAF1UBX molecules can be superimposed onto
the corresponding residues in the p97N-FAF1UBX complex
with an rmsd of 0.60 A˚ (A), 0.85 A˚ (B), 0.64 A˚ (C), and 0.74 A˚
(D) calculated over 80 aligned residues. Interestingly, in all four
monomers Pro640 is already in the cis-configuration (Figures
2A and 2B). However, the superimposed structures revealed
differences for the FPR loop containing Pro620. This region, 833–843, June 8, 2011 ª2011 Elsevier Ltd All rights reserved 835
Figure 2. Comparison of FAF1UBX in Complex with p97N and in the Apo State
(A) Superposition of the FAF1UBX apo structure with FAF1UBX in complex with p97N (colored in gold) shown as a ribbon representation (see also Figure S1). The
four UBXmonomers present in the asymmetric unit are superimposed and are colored in purple (chain A), green (chain B), blue (chain C), and pink (chain D). p97N
is shown in a surface representation. The two Phe-Pro dipeptides containing the cis/trans bonds are shown in stick representation.
(B) The trans- and cis-isomers of Pro620 in the apo structure are superimposed onto the corresponding residues in the complex structure and are colored as in (A).
(C) SIGMAA-weighted FoFc omit electron density map of the S3/S4 loop contoured at three times the rmsd. Residues 618–621 were omitted from
the model.
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molecules (chains B and D) having the critical FPR loop in the
cis-configuration and the remaining two (A and C) in the trans-
configuration. In the B chain the loop is stabilized by an adjacent
molecule, whereas it is more solvent exposed in chain D as it is in
chains A and C. This indicates that the FAF1UBX domain in the
absence of p97 displays conformational variability with Pro620
being present in both the cis- and trans-configuration and that
p97 selects the cis-isomer upon binding. The cis-configuration
of Pro620 seems to be essential for binding of the FAF1UBX
domain to p97 because the trans-isomer would lead to either
severe steric clashes with Arg53 of p97N, or Phe619 would not
stretch into the binding cleft and would stay solvent exposed
(Figure 2A). Because Phe619 is one of the key residues in p97
interaction, this would disrupt the binding of the FAF1UBX
domain to p97 (see below). The observations regarding the
mixture of cis- and trans-isomers in the isolated state are in
excellent agreement with another crystal structure of the
FAF1UBX domain, which has just been published (Kang and
Yang, 2011).
In contrast to the FAF1UBX structure, in the UBX domain of
p47 in complex with p97ND1 (Dreveny et al., 2004), the crucial
proline in the S3/S4 loop has been modeled in the trans-config-
uration. In this structure the conserved FPR loop can theoreti-
cally bind into the hydrophobic N domain pocket with the proline
in either cis or trans, which is due to the fact that in the UBX836 Structure 19, 833–843, June 8, 2011 ª2011 Elsevier Ltd All rightsdomain of p47, the second arginine of the conserved R.FPR
motif is replaced by asparagine. The shorter side chain of this
residue would allow for enough rotational/conformational flexi-
bility to adopt both configurations in the complex. In contrast
the longer side chain of FAF1 Arg621 that compacts the loop
most likely requires the cis-isomer. In our p97N-FAF1UBX
crystal structure, a partial disorder of this loop resulting in
a conformational heterogeneity is observed despite the unam-
biguous assignment of the cis-proline. Although this loop was
modeled in two conformations that differ by a flip in the peptide
between residues Thr618 and Phe619 (Figure 2C), weak addi-
tional difference density is still visible, reflecting an increased
mobility that might be important for interaction. Interestingly,
the solution structure of the UBX domain of UBXD7 (PDB entry
2DLX), which shares 35% sequence identity with FAF1UBX,
features both prolines (Pro620 and Pro640 of FAF1) in the
cis-configuration.
A Conserved Binding Mode for p97N Adaptor Proteins
The structures of p97N in complex with the FAF1UBX domain
(this study) as well as the structure of p47UBX-p97ND1 (Dreveny
et al., 2004) and an NMR-derived model of the NPL4 N-terminal
ubiquitin-like domain (ULD) in complex with p97N (Isaacson
et al., 2007) show that, so far, all characterized adaptor proteins
bind to the same hydrophobic cleft formed between the two
N-terminal subdomains of p97 (Figure 3A). As mentioned earlier,reserved
Figure 3. Adaptor Protein Binding to p97
(A) Ribbon representations together with themolecular surface of p97N colored according to electrostatic potential (electropositive in blue, electronegative in red,
contoured at ± 10 kT) in complex with FAF1UBX (this study, gold), p47UBX (PDB entry 1S3S, colored in blue), and NPL4 ULD (PDB entry 2PJH, colored in
magenta).
(B) Close-up view showing the common p97N-binding surface important for FAF1UBX and p47UBX interaction. Key residues involved in the respective inter-
action are shown in a stick representation with p97N in light (FAF1UBX complex) and dark gray (p47UBX complex), FAF1UBX in gold, and p47UBX in blue.
(C) Structure-based sequence alignment of the FAF1UBX and p47UBX domains. Secondary structure elements of FAF1UBXwere assigned using DSSP (Kabsch
and Sander, 1983) and are labeled above the sequences. The alignment was performed using DaliLite (Holm et al., 2008), and the figure was prepared with
ESPript (Gouet et al., 1999). Strictly conserved amino acids are highlighted with a red background and similar amino acids as red letters. Residues involved in p97
interaction are labeled with gold stars (FAF1UBX) and blue stars (p47UBX).
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p97 adaptor proteins (Schuberth andBuchberger, 2008), and the
structures of the UBX domains of FAF1 and p47 are likely to
represent a general p97-bindingmechanism for all UBX proteins.
The crystal structures of the FAF1 and p47 UBX domains in
complex with p97 can be superimposed with an rmsd of 1.8 A˚,
and both UBX domains bind via the conserved UBX R.FPR
(R.FPN in p47) motif (Figures 3B and 3C). Additional interacting
residues located in b strands S1 and S5 are not as strongly
conserved (Figure 3C). Both proteins bind in a similar manner
to the p97 interdomain cleft, mediated mainly via hydrophobic
interactions with residues Val38, Phe52, Ile70, Leu72, Tyr110,
and Tyr143 of p97N.
The NPL4 ULD resembles ubiquitin rather than UBX in the
length of its S3/S4 loop but contains an additional 310-helical
insert that provides specific contacts with p97, which distin-
guishes it from both ubiquitin and the UBX domain. The b sheet
of the NPL4 ULD is oriented in such a way that it covers theStructure 19hydrophobic-binding groove (Figure 3A). Nevertheless, all these
ULDs recognize the p97N cleft using similar, yet subtly different
interaction modes. p97N residues common to all interactions
are Phe52, Tyr110, and Tyr143. The loop in ubiquitin that corre-
sponds to the UBX S3/S4 loop is shorter by two residues, which
correspond precisely to the Phe619-Pro620 dipeptide. In addi-
tion, Arg621 is replaced by a glycine that results in a sharp
turn. This might explain why monoubiquitin binds to p97 with
only low affinity (Rape et al., 2001), although it shares the same
overall fold.
FAF1 Assembles into a Ternary Complex with p97
and UFD1/NPL4 via Its UBX Domain
Both the UBA-UBX protein p47 and the heterodimeric UFD1/
NPL4 cofactor use a similar bipartite mechanism that involves
binding via the UBX domain (p47) or ULD (NPL4) and a Shp
box (p47 or UFD1) to the N domain of p97, and hence, both
cofactors compete for p97 binding in vitro (Bruderer et al.,, 833–843, June 8, 2011 ª2011 Elsevier Ltd All rights reserved 837
Figure 4. Interaction of p97 with FAF1
(A) Analytical size exclusion chromatography of p97-FAF1 (upper panel), p97-UFD1/NPL4-FAF1 (bottom panel), and the individual components. p97 (5 mM) was
incubated with UFD1/NPL4 and FAF1 in a 6:3:6 molar ratio. The indicated elution fractions were analyzed by SDS-PAGE followed by Coomassie brilliant blue
staining.
(B) ITC analysis of p97ND1-FAF1 and variants. The domain architecture of FAF1 is shown on top, and the FAF1 variants are indicated. UN, UFD1/NPL4.
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Sequential Cofactor Binding to p972004; Meyer et al., 2000). p47 binds as a trimer where each
monomer is associated with two adjacent p97 protomers
(Beuron et al., 2006). In contrast only one UFD1/NPL4 hetero-
dimer binds to two adjacent protomers of a p97 hexamer (Pye
et al., 2007), thus potentially allowing further cofactors to bind
to nonoccupied N domains. Accordingly, it could be shown
that other UBA-UBX proteins like Ubx2, FAF1, and UBXD7 coim-
munoprecipitate p97 with the UFD1/NPL4 heterodimer and
endogenous ubiquitin conjugates (Alexandru et al., 2008; Schu-
berth and Buchberger, 2005), an observation that is consistent
with the existence of higher-order complexes. We consequently
characterized the putative ternary p97-UFD1/NPL4-FAF1 com-
plex in more detail. Initially, we analyzed the in vitro interaction
between FAF1 and p97 by analytical size exclusion chromatog-
raphy (Figure 4A). Under these conditions complex formation
surprisingly was only observed in the presence of UFD1/NPL4.
Analysis of this ternary complex by SDS-PAGE suggests a sub-
stoichiometric binding of FAF1 and UFD1/NPL4 with respect to
the number of p97 protomers.
To determine the affinity of the interaction between p97-UFD1/
NPL4 and FAF1 as well as the exact stoichiometry of this com-
plex, we used isothermal titration calorimetry (ITC) (Figure 4B
and Table 2). Because ITC analyses with both full-length p97
as well as p97ND1, which lacks the second ATPase domain, re-
vealed no differences in binding affinity, further experiments
were conducted with the truncated hexameric p97ND1 protein.
Again, under these conditions no binding of FAF1 to p97 could
be detected in the absence of UFD1/NPL4. Analysis of the
exothermic-binding curve in the presence of UFD1/NPL4
showed that the best fit is obtained with a one-site binding838 Structure 19, 833–843, June 8, 2011 ª2011 Elsevier Ltd All rightsmodel, yielding a binding stoichiometry (N) for the p97/p97ND1
hexamer of N = 0.18 ± 0.05/0.11 ± 0.07, which is consistent
with the binding of one FAF1 molecule to the p97/p97ND1
hexamer and a dissociation constant (KD) of 2.3 ± 0.22/2.6 ±
0.35 mM. Under the same conditions we could confirm a 6:3
binding stoichiometry (N = 0.38 ± 0.01/0.34 ± 0.01) and a KD of
0.70 ± 0.04/0.54 ± 0.02 mM for the interaction between trimeric
p47 and p97/p97ND1, in agreement with published data (Beuron
et al., 2006). Analysis of the binary p97/p97ND1-UFD1/NPL4
interaction confirmed the proposed 6:1 stoichiometry (N =
0.15 ± 0.02/0.11 ± 0.03) and a KD of 1.7 ± 0.20/2.1 ± 0.18 mM.
Earlier immunoprecipitation experiments showed that the
FAF1 UBX domain is crucial for the interaction with endogenous
p97 (Song et al., 2005). However, at this point it has not been
analyzed whether the multidomain protein FAF1, like p47, uses a
bipartite-bindingmechanism involving twoseparateFAF1-binding
sites or whether its UBX domain solely mediates the interaction
with p97-UFD1/NPL4. A FAF1 variant lacking the N-terminal
substrate-binding UBA domain has no effect on complex forma-
tion (Figure 4B and Table 2). Furthermore, a FAF1UBX variant, in
which the conserved FPR motif was replaced by the SGG motif
found in UBXD1 (Carim-Todd et al., 2001), a UBX protein that
does not interact with p97 via its UBX domain (Kern et al., 2009;
Madsen et al., 2008), completely abolished binding under these
conditions (Figure 4B and Table 2). This result clearly demon-
strates that the interaction of FAF1 with p97-UFD1/NPL4 is not
mediated by a bipartite-binding mechanism and that the UBX
domain constitutes the only binding determinant.
It has been proposed that ATP binding/hydrolysis triggers
conformational changes of the p97N domain that are importantreserved
Table 2. ITC Parameters of p97, p97-UFD1/NPL4, and Interaction Partners
KD (mM) N DG (kcal/mol)
p97ND1 flFAF1 n.d. n.d. n.d.
flp97-UN flFAF1 2.3 ± 0.22 0.18 ± 0.05 7.9
p97ND1-UN flFAF1 2.6 ± 0.35 0.11 ± 0.07 8.0
flp97 p47 0.70 ± 0.04 0.38 ± 0.01 8.5
p97ND1 p47 0.54 ± 0.02 0.34 ± 0.01 8.6
flp97 UFD1/NPL4 1.7 ± 0.20 0.15 ± 0.02 8.1
p97ND1 UFD1/NPL4 2.1 ± 0.18 0.11 ± 0.03 8.0
p97ND1-UN DUBAFAF1 2.2 ± 0.33 0.11 ± 0.08 7.9
p97ND1(R155H-Mg2+/ATPgS)-UNa flFAF1 1.14 ± 0.07 0.17b 8.2
p97ND1-UN flFAF1UBX(FPR/ SGG) n.d. n.d. n.d.
flp97-UN flUBXD7 3.1 ± 0.40 0.22 ± 0.08 7.6
p97ND1-UN flUBXD7 2.0 ± 0.24 0.24 ± 0.06 7.9
p97ND1-UN FAF1UBX 1.5 ± 0.42 0.27 ± 0.06 7.9
All numbers shown are averages of two experiments using independent protein preparations. The errors represent the larger experimental uncertainty
of the two measurements given by the Origin software following curve fitting of the experimental data. N, binding stoichiometry; n.d., no binding
detected; UN, UFD1/NPL4; fl, full-length.
a Single experiment with experimental errors.
bN value was fixed before fitting the data to allow accurate determination of the other parameters.
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Sequential Cofactor Binding to p97for adaptor protein binding/release (Rouiller et al., 2000). Anal-
ysis of adaptor protein binding to p97 in the presence or absence
of ATP is complicated due to the fact that isolated p97 typically
has ADP bound at its D1 domain, which cannot be exchanged
(Pye et al., 2006). Recently, it has been shown that IBMPFD
variants undergo a nucleotide-induced conformational change
of the N domain (up and down conformation) in the presence
of the nonhydrolyzable ATP analog ATPgS (Tang et al., 2010).
However, analysis of the p97-R155H variant, the most common
missense mutation found in patients with IBMPFD, did not alter
significantly (2-fold affinity increase) the binding behavior of
UDF1/NPL4 and FAF1 to p97 in the presence of ATPgS (Fig-
ure 4B and Table 2), thus indicating that a general conformational
change of the N domain is not crucial for triggering association/
dissociation of these adaptor proteins but could be important for
interaction with substrates or other proteins.
An analysis of the p97/p97ND1 interaction with UBXD7,
another UBA-UBX protein, revealed the same UFD1/NPL4-
dependent binding behavior resulting in a 6:1:1 stoichiometry
for the ternary p97-UFD1/NPL4-UBXD7 complex with a binding
stoichiometry of N = 0.22 ± 0.08/0.24 ± 0.06 and a KD of 3.1 ±
0.40/2.0 ± 0.24 mM (Table 2). Based on analytical size exclusion
chromatography, ITC, and crosslinking experiments (data not
shown), a stable UFD1/NPL4-FAF1 interaction has not been
observed, suggesting that p97 undergoes conformational
changes upon binding of UFD1/NPL4 that allow for the subse-
quent binding of FAF1. The data presented here reveal a hier-
archy in cofactor binding with the UFD1/NPL4 heterodimer
preceding the UBA-UBX proteins.
Analysis of the p97N-FAF1UBX Complex Interface
To further probe the interaction between FAF1 and p97, we
analyzed the importance of interface residues identified in the
p97N-FAF1UBX complex structure by site-directed mutagen-
esis and subsequent binding assays using p97ND1 andStructure 19FAF1UBX variants. The contribution of these residues was
initially studied in pull-down binding assays in the absence of
UFD1/NPL4. In contrast to full-length-FAF1, binding of the iso-
lated UBX domain does not strictly depend on the presence of
this cofactor, which also explains why we were able to obtain
the complex structure. However, one should keep in mind that
protein concentrations during crystallization were significantly
higher than during ITC and size exclusion chromatography
experiments, thus compensating for the reduced affinity of the
p97-FAF1 interaction in the absence of UFD1/NPL4. Residues
involved in hydrophobic interactions (Val38, Phe52, Ile70,
Leu72, and Tyr110) revealed a significantly reduced binding to
FAF1UBX (Figure 5A). Interestingly, the exchange of Arg53,
which apparently stabilizes the conformation of the S3/S4
loop, with alanine does not lead to a destabilization of the
complex, indicating that hydrophobic interactions, although
they only constitute 25% of the binding interface, are the key
driving forces for this interaction. Analysis of FAF1UBX variants
showed a largely reduced binding for residues located in the
conserved 579R.619FPR621 motif (Figure 5B).
ITC studies with p97ND1 and the UBX domain of FAF1 re-
vealed only a weak exothermic reaction and low binding affinity
resulting in a KD value of 30 mM. Similar to full-length FAF1, the
isolated UBX domain also needs UFD1/NPL4 for high-affinity
binding (KD = 1.5 ± 0.42 mM) (Table 2). To allow for a direct
comparison with the wild-type complex, the UFD1/NPL4 hetero-
dimer in complex with p97ND1 was utilized for analysis of
the UBX variants. The ITC experiments confirmed the results
obtained in the pull-down assays with variants of the
579R.619FPR621 motif exhibiting affinities, which are reduced
by a factor of 8–13 (Figure 5C). The KD values are 18 mM for
R579A, 20 mM for F619A, and 12 mM for R621A compared to
wild-type UBX with a KD of 1.5 mM, whereas the F645A variant
with a KD of 1.6 mM showed no effect (Figure 5C). As shown
above, the conserved Pro620 in the S3/S4 loop, as well as, 833–843, June 8, 2011 ª2011 Elsevier Ltd All rights reserved 839
Figure 5. Analysis of the p97N-FAF1UBX Interface
(A) His-tag pull-down assays of p97ND1 variants: His-tagged p97ND1wild-type (WT) and indicated variants were used. Binding of FAF1UBXWTwas analyzed by
SDS-PAGE of the reaction mixture followed by Coomassie brilliant blue staining. FAF1UBX alone was included as a control to estimate the amount of nonspecific
UBX binding (labeled control), and a loading control for FAF1UBX (labeled UBX) is shown.
(B) His-tag pull-down assays of FAF1UBX variants: His-tagged p97ND1 WT was used. Binding of FAF1UBX WT and indicated variants was analyzed as in (A).
(C) ITC analysis of FAF1UBX binding to p97ND1 in the presence of UFD1/NPL4 (UN) and UBX mutants.
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Sequential Cofactor Binding to p97Pro640 in the 310/S5 loop, is in the cis-configuration, which
seems to be important for interaction with p97 (Figure 2). Indeed,
an exchange of either FAF1UBX proline (Pro620 or Pro640) with
asparagine, a residue that strongly favors the trans-conformation
yet can stabilize b turns via backbone hydrogen bonds, com-
pletely abolished binding under these conditions in the case of
Pro620 as measured by ITC, or caused a 7-fold reduction in
affinity in the case of Pro640 with a KD of 10 mM for the P640N
mutant compared to 1.5 mM for the wild-type (Figure 5C). Due
to the fact that NPL4 and the UBX domain of FAF1 share overlap-
ping binding sites (see above), the p97ND1 variants could not be
analyzed by ITC because they would also prevent binding of
UFD1/NPL4.
DISCUSSION
UBX domain-containing cofactors represent the largest group
of p97-binding partners. At present only the structure of the
p97ND1-p47UBX complex is available; however, the UBX
domain of p47 deviates from the canonical R.FPR motif in the
last residue, which is asparagine instead of arginine. In agree-
ment with the p97-p47 complex, our data show that the crucial840 Structure 19, 833–843, June 8, 2011 ª2011 Elsevier Ltd All rightsdeterminants of UBX domain binding to the N domain of p97
are provided by the UBX 579R..619FPR621 signaturemotif (residue
numbers refer to the FAF1 UBX domain). In contrast to the UBX
domain of p47, the FPR motif adopts a cis-proline configuration,
which, based on site-directed mutagenesis data, is essential for
binding and allows the aromatic ring of Phe619 to insert into the
hydrophobic interdomain cleft of p97N. Both arginines deeply
stretch into the p97-binding pocket to anchor the UBX domain
and to stabilize the complex by essential hydrophobic interac-
tions (Figure 1C). Nearly all UBX domains contain an arginine,
or less frequently a lysine, at the position corresponding to
Arg579 of FAF1, and a hydrophobic residue followed by a proline
in the S3/S4 loop, thus indicating the functional importance of
these residues (Buchberger et al., 2001). The second arginine
(Arg621 in FAF1) is conserved in all UBA-UBX proteins with the
exception of p47, and we predict that in those proteins the
proline is always in the cis-configuration.
One of the key questions regarding the biological function of
p97 is how this highly versatile ATPase participates in many
dissimilar physiological processes. It is clear that answers to
this question can only be gained by studying the interaction of
p97 and its structurally diverse adaptor proteins. It has beenreserved
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Sequential Cofactor Binding to p97reported that some adaptor proteins that target identical or over-
lapping sites on p97 bind in a mutually exclusive manner,
including the substrate-recruiting cofactors p47 and UFD1/
NPL4 (Bruderer et al., 2004; Meyer et al., 2000). However, these
proteins can combine with additional cofactors to form distinct
assemblies of p97-protein complexes (Alexandru et al., 2008;
Schuberth and Buchberger, 2008), as shown in this study for
the p97-UFD1/NPL4-FAF1 and p97-UFD1/NPL4-UBXD7 com-
plexes, thus suggesting that simple competition for p97-binding
sites is unlikely to be the only determinant in cofactor selectivity.
Although it has been proposed that nucleotide-induced confor-
mational changes of the p97N domain can trigger assembly/
disassembly of adaptor proteins (Rouiller et al., 2000), our
studies with the most prevalent IBMPFD variant (p97-R155H)
suggested that a general conformational change of the N domain
is not crucial for association/dissociation of the FAF1 or UBXD7
adaptor proteins.
Instead, our data clearly demonstrate a hierarchical binding to
p97 for the two UBA-UBX containing adaptor proteins. Two
distinct mechanisms could explain why binding of the UBX
domain-containing cofactors FAF1 and UBXD7 require preas-
sembly of the UFD1/NPL4 heterodimer with p97: (1) the UFD1/
NPL4 complex when bound to p97 provides additional interac-
tion sites for FAF1 and UBXD7 so that high-affinity binding of
these proteins requires not only the complementary surface
between p97 and the UBX domain described in this work but
also a direct interaction between UFD1/NPL4 and the UBA-
UBX containing cofactors FAF1 and UBXD7; and (2) binding of
UFD1/NPL4 induces conformational changes in p97, resulting
in an asymmetry in p97 so that only one of the vacant p97
subunits interacts tightly with FAF1 or UBXD7. According to
this model, FAF1/UBXD7 binding does not have to occur adja-
cent to the UFD1/NPL4 heterodimer but requires the presence
of the UFD1/NPL4 cofactor. Our data currently do not allow us
to formally rule out one of these models. However, the observa-
tion that binding of the isolated UBX domain of FAF1 to p97 also
requires the presence of UFD1/NPL4 renders the first model less
likely because a potential UFD1/NPL4-FAF1 interaction would
be restricted to the UBX domain, which constitutes only one-
eighth of the total FAF1 residues. This assumption is also sup-
ported by our inability to crosslink the UFD1/NPL4-FAF1
proteins. Nevertheless, additional biochemical and structural
studies are required to establish themolecular details of the hier-
archy in cofactor binding to p97 described here for the first time.
The hierarchical binding of cofactors to p97 provides an addi-
tional layer of specificity control for cellular processes involving
UFD1/NPL4. As was first shown for yeast Ubx2, UBA-UBX co-
factors have the potential to regulate the subcellular localization
and/or substrate range of the p97-UFD1/NPL4 complex (Neuber
et al., 2005; Schuberth and Buchberger, 2005, 2008). Such a
control mechanism is not only consistent with the hierarchical
binding model described here but in fact critically requires it.
Otherwise, yeast Ubx2 and other UBA-UBX cofactors would
be able to recruit p97 complexes lacking UFD1/NPL4, which,
at least in the case of Ubx2 and the ERAD pathway, would result
in nonfunctional, potentially dominant-negative p97 assemblies.
Conversely, the hierarchical binding model predicts that cellular
functions of yeast Ubx2, mammalian FAF1, and UBXD7 should
strictly depend on UFD1/NPL4. While this is clearly the caseStructure 19for Ubx2, an involvement of UFD1/NPL4 in the UBXD7-depen-
dent turnover of HIF-1a and in the degradation of FAF1 targets
remains to be addressed experimentally. Interestingly, a number
of additional mammalian UBA-UBX proteins were found to bind
to p97 and UFD1/NPL4 (Alexandru et al., 2008), suggesting that
they also could bind in a hierarchical manner to the p97-UFD1/
NPL4 complex to direct it to still unknown targets.
EXPERIMENTAL PROCEDURES
Cloning and Site-Directed Mutagenesis
The following constructs were used in this study: full-length FAF1 (aa 1–650),
FAF1DUBA (aa 98–650), and FAF1UBX (aa 568–650) (pETM11, EMBL Heidel-
berg, PciI/XhoI, N-terminal His-tag); full-length p97 (aa 1–806) and p97N (aa 1–
187) (pProEx_HTA, Invitrogen, KasI/HindIII, N-terminal His-tag); p97ND1 (aa
1–480) (pET21b, Novagen, NdeI/SalI, C-terminal His-tag); UBXD7 (modified
pRSET A, Invitrogen, BamHI/EcoRI, N-terminal His-tag); UFD1 (pET-Duet, No-
vagen, NcoI/HindIII, N-terminal His-tag); and NPL4 (pCOLA-Duet, Novagen,
NcoI/EcoRI). For site-directed mutagenesis of FAF1UBX and p97ND1, the
QuikChange II Site-Directed Mutagenesis Kit from Agilent was used.
Protein Expression and Purification
All proteins were expressed in E. coli BL21(DE3) RIL cells (Novagen) by induc-
tion with 0.5–1 mM IPTG at an OD600 of 0.6 overnight at 16
C. UFD1 and NPL4
were coexpressed. Proteins were purified in 50 mM Tris (pH 8), 150 mM KCl,
5% (v/v) glycerol, 5 mMMgCl2 buffer (buffer A), and 5 mM b-mercaptoethanol
by metal affinity chromatography (Ni-NTA, Invitrogen; Ni-TED, Macherey-
Nagel) and size exclusion chromatography (Superdex 200, Superose 6, GE
Healthcare). Prior to size exclusion chromatography, FAF1UBX, full-length
p97, and its N domain were dialyzed at 4C overnight in the presence of TEV
protease (1:50) followed by Ni-NTA chromatography to remove uncleaved
proteins as well as His-tagged TEV protease. All proteins were concentrated
to 10 mg/ml by ultrafiltration (Vivaspin, Sartorius), shock frozen, and stored
at 80C.
Crystallization
For crystallization of the p97N domain in complex with the FAF1UBX domain,
both proteins were incubated at a molar ratio of 1:2 for 1 hr at 4C and concen-
trated to 10 mg/ml. Crystals were grown by vapor diffusion in hanging drops
containing equal volumes of protein in buffer A and 5 mM dithiothreitol
(DTT), and a reservoir solution consisting of 16%–20% (w/v) polyethylene
glycol monomethyl ether 2000, 0.2 M trimethyl-N-oxide and 0.1 M Tris (pH
8.5) equilibrated against the reservoir solution. Crystals belong to space group
P65 with approximate cell dimensions of a = b = 88.1 A˚ and c = 66.9 A˚ with one
complex per asymmetric unit. Crystals of the p97N domain (9.5 mg/ml) were
obtained in 1 M 1,6-hexanediol, 0.1 M Na-acetate (pH 4.5), and 0.01 M
CoCl2. They belong to space group P31 with approximate cell dimensions of
a = b = 60.6 A˚ and c = 63.1 A˚ with one molecule per asymmetric unit. Crystals
of the FAF1UBX domain (50 mg/ml) were obtained in 0.4 M NaH2PO4/1.6 M
K2HPO4, 0.1 M imidazole (pH 8.0) and 0.2 M NaCl, which belong to space
group P61 with approximate cell dimensions of a = b = 92.6 A˚ and c =
108.5 A˚ containing four molecules per asymmetric unit.
Data Collection and Structure Determination
Crystals were cryoprotected by soaking in mother liquor supplemented with
15%–30% (v/v) glycerol, flash cooled in liquid nitrogen, and data collection
was performed at 100 K. Data were collected at beamlines BL 14.1 (BESSY,
Berlin) and ID23-1 (ESRF, Grenoble) and processed using iMosflm and
Scala (Evans, 2006; Leslie, 1992). Data collection statistics are summarized
in Table 1. For subsequent calculations the CCP4 suite and PHENIX were
utilized (Adams et al., 2010; CCP4, 1994) with exceptions as indicated. The
structures were solved by molecular replacement using Phaser (McCoy
et al., 2007) with the N domain of p97 (PDB entry 1S3S) and the UBX domain
of FAF1 (PDB entry 1H8C) as search models. The structure of apo FAF1UBX
was solved with the FAF1UBX crystal structure (this work) as search model.
The structures were refined with PHENIX incorporating TLS refinement.
Solvent molecules were automatically added with PHENIX. For model building, 833–843, June 8, 2011 ª2011 Elsevier Ltd All rights reserved 841
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Sequential Cofactor Binding to p97and fitting, Coot was used (Emsley and Cowtan, 2004). The figures were
generated with PyMOL (http://www.pymol.org).
In Vitro Binding Assays
For pull-down assays, His-tagged p97ND1 and variants were immobilized on
Ni-NTA beads. In all experiments, 40 ml of beads were incubated with 5 mM of
purified p97ND1 in 400 ml of Tris-buffered saline (TBS) with 1 mM DTT and
0.1% (v/v) Triton X-100 at 4C for 2 hr. After centrifugation (1250 3 g, 30 s),
beads were washed four times with 400 ml of binding buffer. Purified UBX
proteins (25 mM) in a total volume of 400 ml of binding buffer were added to
immobilized p97ND1 and treated in the same way as in the first step. Immobi-
lized proteins were directly analyzed by 18% (v/v) SDS-PAGE. FAF1UBX alone
was included as control to estimate the amount of nonspecific UBX binding.
ITC experiments were conducted as described (Ha¨nzelmann et al., 2010) using
50 mM Tris (pH 8), 150 mM KCl, and 1 mM b-mercaptoethanol as buffer. In all
experiments, 75–150 mMof ligands was titrated into the sample cell containing
5–10 mM of full-length p97/p97ND1 or full-length p97/p97ND1-UFD1/NPL4.
Complex formation was analyzed by analytical size exclusion chromatography
(Superose 6, GE Healthcare). p97 (5 mM) or p97-UFD1/NPL4 (6:3 molar ratio)
was incubated with FAF1 at a 6:6 (p97:FAF1) molar ratio for 1 hr on ice. Size
exclusion chromatography experiments were performed in 50 mM Tris
(pH 8.0), 150 mM KCl, and 1 mM b-mercaptoethanol.
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